Versius extends DEPLOY's surgical cluster along a second axis: where the Wave 1 triangle (da Vinci, Hugo, Ottava) varies by FDA-clearance posture in general laparoscopy, Versius adds clinical-domain and geography variance, the international-soft-tissue archetype with a modular multi-arm architecture distinct from da Vinci's monolithic design.
✔
Its commercial footprint is genuinely international (CE-marked across Europe, Latin America, AMEA, and Australia), and it is now US-FDA-cleared for cholecystectomy (De Novo October 2024; Versius Plus 510(k) December 2025).
There is no consumer price. Versius is enterprise B2B surgical equipment sold to hospitals on per-system contracts, so DEPLOY records zero price points rather than a consumer figure.
Versius is sold to hospitals, not consumers. From UK-based CMR Surgical, it is CE-marked and commercial across Europe, Latin America, AMEA, and Australia, and US-FDA-cleared for cholecystectomy (De Novo, October 2024; Versius Plus 510(k), December 2025).
Real-world status
CMR Surgical's Versius (and Versius Plus) is a modular, multi-arm, soft-tissue minimal-access surgical robot and the international-soft-tissue archetype of DEPLOY's surgical cluster. Its modular multi-arm architecture is a deliberate contrast to the monolithic design of Intuitive's da Vinci: it is teleoperated and software-driven, capturing telematic, video, and outcome data. On regulatory status: Versius is US-FDA-cleared for cholecystectomy via a De Novo authorization in October 2024, with Versius Plus cleared via 510(k) on December 18, 2025, and a gynecology 510(k) submitted April 29, 2026 (pending). It is not broadly 'US-pending'; only the gynecology indication is.
A correction to common framing: Versius is not broadly 'US-pending'. It is US-cleared for cholecystectomy; only the gynecology indication (510(k) submitted April 2026) is pending. Read the cleared scope by indication, not as a blanket status.
⊘
There is no consumer price. Versius is sold to hospitals on per-system contracts, so DEPLOY records zero price points.
No⊘absence. It is enterprise B2B surgical equipment sold to hospitals on per-system contracts; there is no consumer price.
Is the Versius FDA-cleared in the US?
Yes, for cholecystectomy🟢verified: a De Novo authorization (October 2024) plus a Versius Plus 510(k) (December 2025). A gynecology 510(k) was submitted April 2026 and is pending.
How is Versius different from da Vinci?
Versius is modular multi-arm🟢verified, a deliberate contrast to da Vinci's monolithic design; both are teleoperated soft-tissue systems.
Where is Versius used?
CE-marked and commercial across Europe, Latin America, AMEA, and Australia🟢verified, plus US clearance for cholecystectomy.
How does Versius compare to the rest of the cluster?
It is the international-soft-tissue archetype🟢verified; the Wave 1 triangle (da Vinci, Hugo, Ottava) varies by FDA posture, while Versius adds geography and a modular architecture.
Pricing and availability are tagged verified or claimed against primary sources. Manufacturer targets are reported as targets, not prices you can pay today.